Certara Products - Simcyp Archives | Page 8 of 23 | Certara

Video

PBPK modeling supports approval of breakthrough cancer drug

Pharmacyclics’ (now AbbVie) Imbruvica (ibrutinib) is an anticancer drug targeting B-cell malignancies. Leveraging the US…

CertaraOctober 23, 2020

Brochure

Simcyp Drug Labels

CertaraOctober 23, 2020

Brochure

Simcyp PBPK Consulting Services

CertaraOctober 23, 2020

Publication

Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy

Model-informed precision dosing (MIPD) has become synonymous with modern approaches for individualizing drug therapy, in…

CertaraOctober 12, 2020

On-Demand Webinar

Intro to Smart In Silico Tools to Aid in Translating In Vitro & In Vivo Studies

Safety issues account for about a quarter of the attrition in drug projects, and can…

CertaraOctober 5, 2020

Fact Sheet

Secondary Intelligence

Predicts off-target risks, streamlining secondary pharmacology analysis for safer drug development.

CertaraSeptember 4, 2020

Publication

VIVD: Virtual in vitro distribution model for the mechanistic prediction of intracellular concentrations of chemicals in in vitro toxicity assays

CertaraJune 28, 2020

On-Demand Webinar

Simcyp: 20 Years of Innovation

CertaraJune 27, 2020

On-Demand Webinar

How to Demonstrate Virtual Bioequivalence for Complex Dermal Generic Drugs

This webinar will explain how Certara expanded its PBPK Simcyp Simulator to incorporate an extensive…

CertaraJanuary 24, 2020

Poster

Predicting Human Oral Bioavailability: Comparison of In Vivo Animal (Rat- Dog- and Monkey) Studies versus Mechanistic In Vitro In Vivo Extrapolation (IVIVE) Based Predictions

CertaraNovember 6, 2019

© 2025 Certara. All Rights Reserved. | Privacy policy